MX2014002363A - Formulaciones de antigenos de staphylococcus aureus con adyuvante. - Google Patents
Formulaciones de antigenos de staphylococcus aureus con adyuvante.Info
- Publication number
- MX2014002363A MX2014002363A MX2014002363A MX2014002363A MX2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A
- Authority
- MX
- Mexico
- Prior art keywords
- staphylococcus aureus
- aureus antigens
- adjuvanted formulations
- metal salt
- aureus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se puede mejorar la eficiencia de las vacunas de S. aureus al mezclar con adyuvante antígenos de S. aureus con una mezcla de un agonista de TLR (de manera preferente un agonista de TLR7) y una sal metálica insoluble (de manera preferente una sal de aluminio). El agonista de TLR se adsorbe típicamente a la sal metálica. También se puede absorber un antígeno de S. aureus a la sal metálica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530162P | 2011-09-01 | 2011-09-01 | |
US201261607999P | 2012-03-07 | 2012-03-07 | |
PCT/EP2012/067032 WO2013030378A1 (en) | 2011-09-01 | 2012-08-31 | Adjuvanted formulations of staphylococcus aureus antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014002363A true MX2014002363A (es) | 2014-04-14 |
Family
ID=46763095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002363A MX2014002363A (es) | 2011-09-01 | 2012-08-31 | Formulaciones de antigenos de staphylococcus aureus con adyuvante. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140363461A1 (es) |
EP (1) | EP2763695A1 (es) |
JP (1) | JP2014525429A (es) |
KR (1) | KR20140066212A (es) |
CN (1) | CN104093418A (es) |
AU (1) | AU2012300765A1 (es) |
BR (1) | BR112014004782A2 (es) |
CA (1) | CA2847204A1 (es) |
IL (1) | IL231104A0 (es) |
IN (1) | IN2014CN02152A (es) |
MX (1) | MX2014002363A (es) |
RU (1) | RU2014112343A (es) |
SG (1) | SG11201400210RA (es) |
WO (1) | WO2013030378A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010115175A1 (en) * | 2009-04-03 | 2010-10-07 | Momenta Pharmaceticals, Inc. | Control of copolymer compositions |
ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
EP2672989A4 (en) * | 2011-02-08 | 2015-03-11 | Integrated Biotherapeutics Inc | IMMUNOGENIC COMPOSITION WITH ALPHA-HEMOLYSIN OLIGOPEPTIDES |
JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
CA2847204A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
CA2865759C (en) * | 2012-03-07 | 2020-07-21 | Novartis Ag | Immunologically useful arginine salts |
CN104159602B (zh) | 2012-03-08 | 2017-10-24 | 葛兰素史密丝克莱恩生物有限公司 | 加强疫苗的含佐剂制剂 |
WO2014033193A1 (en) * | 2012-08-31 | 2014-03-06 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
TR201910573T4 (tr) * | 2012-08-31 | 2019-08-21 | Glaxosmithkline Biologicals Sa | Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. |
WO2015140108A1 (en) * | 2014-03-17 | 2015-09-24 | Gaxosmithkline Biologicals Sa | Immunising against staphylococcal bone and joint infections |
SI3122378T1 (sl) * | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals S.A. | Mutantni stafilokokni antigeni |
BE1022875B1 (fr) * | 2014-03-26 | 2016-09-30 | Glaxosmithkline Biologicals S.A. | Compositions pour une immunisation contre staphylococcus aureus |
CN105646681B (zh) * | 2016-01-21 | 2021-07-16 | 浙江海隆生物科技有限公司 | 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用 |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE67769T1 (de) | 1983-01-25 | 1991-10-15 | Ciba Geigy Ag | Neue peptidderivate. |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
WO1994021292A1 (en) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
NZ570750A (en) | 2003-07-24 | 2009-12-24 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
US20060188515A1 (en) | 2003-07-24 | 2006-08-24 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphylococcus aureus |
US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
US20090099216A1 (en) | 2005-09-22 | 2009-04-16 | Astrazeneca Aktiebolag A Corporation Of Sweden | Novel adenine compound |
EP1939198A4 (en) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
JPWO2007034917A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
WO2007093901A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
CA2655133C (en) | 2006-06-12 | 2018-03-20 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
JP2009542645A (ja) | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
WO2008005555A1 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
US20100120799A1 (en) | 2007-02-19 | 2010-05-13 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
EP2188280B1 (en) | 2007-08-03 | 2011-03-09 | Pfizer Limited | Imidazopyridinones |
JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
NZ588191A (en) | 2008-03-03 | 2012-06-29 | Irm Llc | Compounds and compositions as tlr activity modulators |
NZ599446A (en) | 2008-03-24 | 2013-11-29 | 4Sc Discovery Gmbh | Novel substituted imidazoquinolines |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
NZ612315A (en) * | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
CA2766629C (en) * | 2009-06-22 | 2020-03-24 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
WO2011007004A1 (en) | 2009-07-16 | 2011-01-20 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Treatment of infections |
GB0913681D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
TWI445708B (zh) * | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
ES2443952T3 (es) * | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
JP6191082B2 (ja) * | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
CA2847204A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
JP2015510872A (ja) * | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
CN104159603A (zh) * | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 |
CN104159602B (zh) * | 2012-03-08 | 2017-10-24 | 葛兰素史密丝克莱恩生物有限公司 | 加强疫苗的含佐剂制剂 |
JP2015528456A (ja) * | 2012-08-31 | 2015-09-28 | ノバルティス アーゲー | Staphylococcusaureusに対する免疫化のための安定化されたタンパク質 |
TR201910573T4 (tr) * | 2012-08-31 | 2019-08-21 | Glaxosmithkline Biologicals Sa | Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. |
WO2014033193A1 (en) * | 2012-08-31 | 2014-03-06 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
US9526776B2 (en) * | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
GB201219420D0 (en) * | 2012-10-29 | 2012-12-12 | Novartis Ag | Staphyloccal immunogens |
BR112015018014A2 (pt) * | 2013-02-01 | 2017-07-11 | Glaxosmithkline Biologicals Sa | liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll |
WO2015140108A1 (en) * | 2014-03-17 | 2015-09-24 | Gaxosmithkline Biologicals Sa | Immunising against staphylococcal bone and joint infections |
SI3122378T1 (sl) * | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals S.A. | Mutantni stafilokokni antigeni |
BE1022875B1 (fr) * | 2014-03-26 | 2016-09-30 | Glaxosmithkline Biologicals S.A. | Compositions pour une immunisation contre staphylococcus aureus |
-
2012
- 2012-08-31 CA CA2847204A patent/CA2847204A1/en not_active Abandoned
- 2012-08-31 EP EP12753488.1A patent/EP2763695A1/en not_active Withdrawn
- 2012-08-31 JP JP2014527686A patent/JP2014525429A/ja active Pending
- 2012-08-31 CN CN201280053918.1A patent/CN104093418A/zh active Pending
- 2012-08-31 WO PCT/EP2012/067032 patent/WO2013030378A1/en active Application Filing
- 2012-08-31 KR KR1020147008622A patent/KR20140066212A/ko not_active Application Discontinuation
- 2012-08-31 IN IN2152CHN2014 patent/IN2014CN02152A/en unknown
- 2012-08-31 MX MX2014002363A patent/MX2014002363A/es unknown
- 2012-08-31 BR BR112014004782A patent/BR112014004782A2/pt not_active IP Right Cessation
- 2012-08-31 US US14/240,616 patent/US20140363461A1/en not_active Abandoned
- 2012-08-31 RU RU2014112343/10A patent/RU2014112343A/ru not_active Application Discontinuation
- 2012-08-31 AU AU2012300765A patent/AU2012300765A1/en not_active Abandoned
- 2012-08-31 SG SG11201400210RA patent/SG11201400210RA/en unknown
-
2014
- 2014-02-24 IL IL231104A patent/IL231104A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201400210RA (en) | 2014-03-28 |
CN104093418A (zh) | 2014-10-08 |
EP2763695A1 (en) | 2014-08-13 |
IN2014CN02152A (es) | 2015-09-04 |
WO2013030378A1 (en) | 2013-03-07 |
JP2014525429A (ja) | 2014-09-29 |
AU2012300765A1 (en) | 2014-03-13 |
BR112014004782A2 (pt) | 2017-03-21 |
CA2847204A1 (en) | 2013-03-07 |
KR20140066212A (ko) | 2014-05-30 |
IL231104A0 (en) | 2014-04-30 |
US20140363461A1 (en) | 2014-12-11 |
RU2014112343A (ru) | 2015-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014002363A (es) | Formulaciones de antigenos de staphylococcus aureus con adyuvante. | |
ZA201500316B (en) | Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof | |
EP3071229A4 (en) | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants | |
EP2680885B8 (en) | Combination vaccines with lower doses of antigen and/or adjuvant | |
HK1202050A1 (en) | Lyophilised and aqueous anti-cd40 antibody formulations cd40 | |
IN2014CN04251A (es) | ||
EP2997246A4 (en) | Piston having combustion bowl shaped to balance combustion efficiency and emission properties | |
MX2015014500A (es) | Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9. | |
BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
EP2992089A4 (en) | Use of anti-cd47 agents to enhance immunization | |
HK1227279A1 (zh) | 在斷奶之前對抗豬繁殖與呼吸綜合徵(prrs)病毒的有效疫苗接種 | |
MX2014010417A (es) | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. | |
EP3089754A4 (en) | Single vial vaccine formulations | |
NZ705606A (en) | Methods for identifying antibodies with reduced immunogenicity | |
HK1197370A1 (en) | Stable immunogenic compositions of staphylococcus aureus antigens | |
MX2015002482A (es) | Composicion inmunogenica. | |
BR112015023523B8 (pt) | Composições farmacêuticas e recipiente de forma de dosagem única | |
EP2726097A4 (en) | HERPES VIRUS VACCINE AND METHOD OF USE | |
WO2014127378A8 (en) | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents | |
EP3010340A4 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
IN2014CN03454A (es) | ||
MY166052A (en) | Freeze-Dried Aripiprazole Formulation | |
WO2013033496A3 (en) | Laser adjuvants for enhancing immune response | |
PT2575872T (pt) | Concentração de antigénios da vacina da gripe sem liofilização | |
EP2968500A4 (en) | VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS |